Abstract
Sacubitril/valsartan has been established as an effective treatment for heart failure (HF) with reduced ejection fraction based on clinical trial data; however, little is known about its use or impact in real-world practice. This study included data from medical and pharmacy claims and medical records review for patients (n = 200) who initiated sacubitril/valsartan between August 2015 and March 2016 preceding issuance of American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) focused update on new pharmacological therapy for HF (May 2016), which included recommendations for sacubitril/valsartan. A within-subject analysis compared symptoms and healthcare resource utilization before and after treatment initiation. Patients treated with sacubitril/valsartan had multiple comorbidities, and nearly all had previous treatment for HF. Most patients initiated sacubitril/valsartan at the lowest dose of 24/26 mg twice a day (BID), which remained unchanged during the observation period for half of the patients. During the first 6 weeks of treatment, few patients discontinued sacubitril/valsartan treatment (5.5%), and only 17% achieved the target dose of 97/103 mg BID after 4 months of t...Continue Reading
References
Jan 9, 2001·Journal of Clinical Epidemiology·C N KlabundeJ L Warren
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jun 12, 2013·Journal of the American College of Cardiology·Clyde W YancyUNKNOWN American Heart Association Task Force on Practice Guidelines
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Dec 19, 2014·Circulation·Dariush MozaffarianUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Nov 26, 2015·The Nursing Clinics of North America·Chad Rogers, Nathania Bush
Feb 16, 2016·Pharmacoepidemiology and Drug Safety·Melissa L SantorelliKitaw Demissie
Feb 27, 2016·F1000Research·Takeshi Kitai, Wh Wilson Tang
Apr 29, 2016·Journal of Managed Care & Specialty Pharmacy·Céline DeschaseauxStuart J Turner
Jul 16, 2016·Journal of the American College of Cardiology·Akshay S DesaiUNKNOWN PARADIGM-HF Investigators
Jan 27, 2017·Circulation·Emelia J BenjaminUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Oct 12, 2017·Advances in Therapy·Nancy M AlbertChun-Lan Chang
Dec 19, 2017·International Journal of Cardiology·Paola BeltránJulio Núñez
Citations
Dec 13, 2018·Journal of Cardiovascular Pharmacology·Amy X DuJustin A Ezekowitz
Apr 27, 2019·Journal of the American Heart Association·Nancy M AlbertChunlan Chang
Jul 11, 2019·Journal of Comparative Effectiveness Research·Herminio Morillas-ClimentAlfonso Valle-Muñoz
Nov 14, 2019·Circulation. Heart Failure·April F MohantyAdam P Bress
Nov 13, 2019·Journal of Cardiovascular Medicine·Seçkin DereliAhmet Kaya
Jan 7, 2020·ESC Heart Failure·Rebabonye B PharithiKenneth McDonald
Apr 4, 2020·Diabetes, Obesity & Metabolism·Javed ButlerJulio Rosenstock
May 30, 2020·British Journal of Clinical Pharmacology·Cormac KennedyMichael Barry
Jun 22, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Antonis S ManolisHelen Melita
Mar 2, 2019·Cardiovascular Drugs and Therapy·Carles Moliner-AbósEulàlia Roig
Nov 28, 2019·Cardiovascular Therapeutics·Helena NorbergKrister Lindmark
Oct 7, 2020·Open Heart·Sashiananthan GanesananthanZaheer Yousef
Jan 21, 2021·Heart Failure Reviews·Stephen J GreeneJaved Butler
Oct 31, 2020·ESC Heart Failure·Rolf WachterAna Filipa Fonseca
Feb 9, 2021·Frontiers in Cardiovascular Medicine·Swathi PathadkaIan C K Wong
Oct 7, 2021·Journal of the American Heart Association·April F MohantyAdam P Bress